Open-Capsule Budesonide for the Treatment of Isolated Immune Checkpoint Inhibitor-Induced Enteritis

Immune checkpoint inhibitors (ICIs) have revolutionized the management of various advanced-stage malignancies. The utilization of ICIs can be limited by their immune-related adverse events such as diarrhea and enterocolitis. Isolated ICI-induced enteritis is an uncommon presentation compared with IC...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussain, Nadeen, Robert, Marie, Al-Bawardy, Badr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553371/
https://www.ncbi.nlm.nih.gov/pubmed/36237281
http://dx.doi.org/10.14309/crj.0000000000000882
_version_ 1784806455235313664
author Hussain, Nadeen
Robert, Marie
Al-Bawardy, Badr
author_facet Hussain, Nadeen
Robert, Marie
Al-Bawardy, Badr
author_sort Hussain, Nadeen
collection PubMed
description Immune checkpoint inhibitors (ICIs) have revolutionized the management of various advanced-stage malignancies. The utilization of ICIs can be limited by their immune-related adverse events such as diarrhea and enterocolitis. Isolated ICI-induced enteritis is an uncommon presentation compared with ICI-induced colitis/enterocolitis. ICI withdrawal and systemic corticosteroids can lead to resolution of enterocolitis in up to 70% of patients. We present a rare case of isolated ICI-induced enteritis refractory to high-dose systemic corticosteroids and responsive to a course of open-capsule budesonide only.
format Online
Article
Text
id pubmed-9553371
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-95533712022-10-12 Open-Capsule Budesonide for the Treatment of Isolated Immune Checkpoint Inhibitor-Induced Enteritis Hussain, Nadeen Robert, Marie Al-Bawardy, Badr ACG Case Rep J Case Report Immune checkpoint inhibitors (ICIs) have revolutionized the management of various advanced-stage malignancies. The utilization of ICIs can be limited by their immune-related adverse events such as diarrhea and enterocolitis. Isolated ICI-induced enteritis is an uncommon presentation compared with ICI-induced colitis/enterocolitis. ICI withdrawal and systemic corticosteroids can lead to resolution of enterocolitis in up to 70% of patients. We present a rare case of isolated ICI-induced enteritis refractory to high-dose systemic corticosteroids and responsive to a course of open-capsule budesonide only. Wolters Kluwer 2022-10-07 /pmc/articles/PMC9553371/ /pubmed/36237281 http://dx.doi.org/10.14309/crj.0000000000000882 Text en © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Case Report
Hussain, Nadeen
Robert, Marie
Al-Bawardy, Badr
Open-Capsule Budesonide for the Treatment of Isolated Immune Checkpoint Inhibitor-Induced Enteritis
title Open-Capsule Budesonide for the Treatment of Isolated Immune Checkpoint Inhibitor-Induced Enteritis
title_full Open-Capsule Budesonide for the Treatment of Isolated Immune Checkpoint Inhibitor-Induced Enteritis
title_fullStr Open-Capsule Budesonide for the Treatment of Isolated Immune Checkpoint Inhibitor-Induced Enteritis
title_full_unstemmed Open-Capsule Budesonide for the Treatment of Isolated Immune Checkpoint Inhibitor-Induced Enteritis
title_short Open-Capsule Budesonide for the Treatment of Isolated Immune Checkpoint Inhibitor-Induced Enteritis
title_sort open-capsule budesonide for the treatment of isolated immune checkpoint inhibitor-induced enteritis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553371/
https://www.ncbi.nlm.nih.gov/pubmed/36237281
http://dx.doi.org/10.14309/crj.0000000000000882
work_keys_str_mv AT hussainnadeen opencapsulebudesonideforthetreatmentofisolatedimmunecheckpointinhibitorinducedenteritis
AT robertmarie opencapsulebudesonideforthetreatmentofisolatedimmunecheckpointinhibitorinducedenteritis
AT albawardybadr opencapsulebudesonideforthetreatmentofisolatedimmunecheckpointinhibitorinducedenteritis

Ejemplares similares